↓ Skip to main content

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy

Overview of attention for article published in Frontiers in oncology, September 2022
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
Published in
Frontiers in oncology, September 2022
DOI 10.3389/fonc.2022.910196
Pubmed ID
Authors

António G. P. Bastos, Bruno Carvalho, Roberto Silva, Dina Leitão, Paulo Linhares, Rui Vaz, Jorge Lima

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 20%
Student > Doctoral Student 1 10%
Student > Master 1 10%
Researcher 1 10%
Student > Postgraduate 1 10%
Other 0 0%
Unknown 4 40%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 30%
Computer Science 1 10%
Agricultural and Biological Sciences 1 10%
Medicine and Dentistry 1 10%
Unknown 4 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2022.
All research outputs
#21,310,332
of 26,170,906 outputs
Outputs from Frontiers in oncology
#11,651
of 22,913 outputs
Outputs of similar age
#324,196
of 437,433 outputs
Outputs of similar age from Frontiers in oncology
#1,040
of 1,795 outputs
Altmetric has tracked 26,170,906 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,433 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,795 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.